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  R
andomized controlled trials 
(RCTs) are generally considered 
to be a robust form of evidence, 
free from bias, and the trial results are 
often used as a powerful tool to promote 
new drugs [1,2]. However, because 
the inclusion criteria for many RCTs 
are often very restrictive (for example, 
trials generally exclude patients with 
serious concomitant illnesses) and 
because patients in trials tend to receive 
better care than those in standard-care 
settings, clinicians should be careful 
about generalizing RCT results to their 
own patients. Unfortunately, many 
drug treatments are widely used in 
clinical practice, sometimes beyond 
the approved indications, even when 
doubts remain about whether the 
results of RCTs of these drugs should be 
generalized. In this article, we discuss 
the use of cholinesterase inhibitors 
in patients with a variety of types of 
dementia and cognitive impairment, 
looking critically at the clinical trial 
evidence on these drugs.
    If the results of these trials are 
not carefully evaluated, together 
with evaluating the methodological 
quality of the studies, this could 
lead to inappropriate prescribing 
of cholinesterase inhibitors. Drug 
companies have invested heavily in 
developing treatments for Alzheimer 
disease, and then were actively 
involved in expanding the market to 
other forms of dementia. In the last 
decade, donepezil, galantamine, and 
rivastigmine have been tested not only 
in patients with Alzheimer disease but 
also in patients with vascular dementia, 
dementia with Lewy bodies, dementia 
associated with Parkinson disease, and 
mild cognitive impairment (MCI). Even 
when the evidence on the efﬁ  cacy of 
these drugs is lacking, or inconclusive, 
the results are often presented in such 
a way as to create a false perception 
of efﬁ  cacy. For example, about 23 
different scales or instruments (on 
average six per trial) were used, in the 
trials considered here, as primary or 
secondary outcome measures. Most of 
them were not validated for the disease 
for which the drugs were tested and are 
not currently used in clinical practice, 
undermining the translation of these 
research ﬁ  ndings into clinical practice. 
Moreover, the treatment effect in the 
trials is usually expressed through the 
average change from baseline in test 
scores, without discussing the clinical 
importance of the usually small effect 
size observed.
  Alzheimer  Disease:  Waiting 
for New Treatments
    The cholinesterase inhibitor donepezil 
was licensed in the US in December 
1996, before the full results of clinical 
trials were available in medical journals 
[3]. The drug was launched with claims 
that it had produced “highly signiﬁ  cant 
improvements in cognitive and clinical 
global assessments” in randomized 
trials lasting 30 weeks and had 
increased the proportion of “treatment 
successes” by 245% in patients with 
mild to moderate Alzheimer disease 
[3]. Donepezil, galantamine, and 
rivastigmine went on to be approved 
in many countries for the treatment 
of Alzheimer disease, even though it 
was clear that the efﬁ  cacy, in the short 
term, was modest, symptomatic, and 
evident only in a subgroup of patients 
[4–8]. 
    In a meta-analysis of randomized, 
double-blind placebo-controlled trials 
of cholinesterase inhibitors, Lanctôt 
and colleagues found that the pooled 
mean proportion of responders to 
drug treatment in excess of that for 
placebo treatment was only 10% (95% 
conﬁ  dence interval, 4%–17%) [9]. 
In this study, response to therapy was 
deﬁ  ned (according to a deﬁ  nition ﬁ  rst 
proposed by the US Food and Drug 
Administration) as an improvement of 
four or more points on the Alzheimer 
Disease Assessment Scale–cognitive 
portion (ADAS-cog) [10]. 
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 Search  Strategy 
    For this article, we searched the 
MEDLINE database from 1996 to 2005 
using the terms donepezil, galantamine, 
and rivastigmine to ﬁ  nd randomized 
controlled clinical trials, systematic 
reviews, and meta-analyses. Our article 
is not itself a systematic review, but we 
discuss all the major RCTs, systematic 
reviews, and meta-analyses of these 
drugs as treatments for Alzheimer 
disease, and we discuss the major RCTs of 
these drugs for other forms of dementia. PLoS Medicine  |  www.plosmedicine.org 0457
    The most recent systematic review 
of RCTs, by Hanna Kaduszkiewicz 
and colleagues, analyzed the 
scientiﬁ  c evidence for the clinical 
use of cholinesterase inhibitors in 
Alzheimer disease, together with 
the methodological quality of the 
trials [11]. The authors concluded 
that the beneﬁ  ts are minimal, the 
methodological quality of the available 
trials is poor, and the scientiﬁ  c basis for 
recommendations of these drugs for 
Alzheimer disease is questionable [11]. 
    A similar conclusion was 
reported in the preliminary draft 
of recommendations on the use of 
cholinesterase inhibitors that is being 
developed by the United Kingdom’s 
National Institute for Health and 
Clinical Excellence (NICE), an 
independent organization responsible 
for providing national guidance on 
treating and preventing illness [12,13]. 
In its preliminary draft appraisal 
document, the organization stated 
“that the RCT evidence on outcomes 
of importance to patients and carers, 
such as quality of life and time to 
institutionalisation, was limited and 
largely inconclusive.” Moreover, the 
NICE committee reported that the 
quality of the reviewed trials was 
mixed, and that “the assessment 
group suspected selection bias, 
measurement bias and attrition bias.” 
The preliminary recommendations 
of the appraisal committee were 
that “donepezil, rivastigmine and 
galantamine are not recommended 
for use in the treatment of mild to 
moderate Alzheimer’s disease,” and 
that further research is required 
to identify subgroups of people for 
whom cholinesterase inhibitors may 
be effective. The committee recently 
updated its guidance, as shown in the 
Sidebar. 
    Patients with Alzheimer Disease 
and Vascular Risk Factors or 
Patients with Vascular Dementia
    The therapeutic potential of 
cholinesterase inhibitors has been 
explored in clinical trials of patients 
with Alzheimer disease with concurrent 
vascular risk factors, and also in 
patients with vascular dementia.
    One 26-week placebo-controlled 
RCT evaluated the efﬁ  cacy and safety 
of rivastigmine for patients with mild 
to moderately severe Alzheimer disease 
with or without concurrent vascular risk 
factors [14]. The authors concluded 
that the drug is effective in patients 
with or without vascular risk factors, 
and that those with vascular risk factors 
“experience greater clinical beneﬁ  t 
(cognition, activities of daily living, 
and disease severity).” However, the 
withdrawal rate was higher for patients 
given the drug than for patients given 
placebo, and there was no intention-to-
treat analysis.
    The effect of galantamine was 
examined in a six-month RCT in a 
mixed population of patients diagnosed 
as having probable vascular dementia, 
Alzheimer disease with cerebrovascular 
disease, or an intermediate diagnosis 
[15]. Unfortunately, the study was 
not powered to detect treatment 
differences in the three subgroups; 
moreover, as in the study on 
rivastigmine [14], the primary statistical 
assessment of efﬁ  cacy was not based on 
an intention-to-treat analysis, but only 
on an observed case analysis.
    Two trials have been conducted to 
evaluate the efﬁ  cacy and tolerability of 
donepezil in patients diagnosed with 
vascular dementia; these trials showed 
modest and inconsistent effects [16,17]. 
The study design was similar to the 
design used in trials of cholinesterase 
inhibitors for Alzheimer disease: the 
vascular dementia trials used similar 
drug doses and similarly lasted only six 
months. As with trials of cholinesterase 
inhibitors for Alzheimer disease, a six-
month trial period is unjustiﬁ  ed for a 
pathology that develops over decades. 
Moreover, the assessment scales used 
in the vascular dementia trials are 
intended for assessing Alzheimer 
disease, and are not validated for the 
evaluation of vascular dementia. The 
investigators did not ﬁ  nd improvement 
for all primary and secondary efﬁ  cacy 
parameters, and a reverse dose effect 
was shown: that is, improvement in 
global function was observed in a 
greater proportion of patients treated 
with donepezil than those treated with 
placebo in the 5-mg group but not in 
the 10-mg group [16]. 
    The study population was, as reported 
by the authors, not typical of all patients 
with vascular dementia (in fact, only 
patients who were stable with respect 
to comorbid conditions, hypertension, 
diabetes, and heart disease were 
included in these clinical trials) [16]. 
Even in this highly selected population, 
an excess of stroke (fatal and nonfatal) 
was observed among treated patients. 
The potential implications for clinical 
practice still remain to be clariﬁ  ed. 
Nevertheless, the drug was presented in 
    Revised draft guidance on the use 
of drugs to treat Alzheimer disease has 
recently been published (23 January 
2006) on the NICE Web site (http://www.
nice.org.uk/page.aspx?o=288826). 
    The preceding draft guidance from 
NICE (http://www.nice.org.uk/page.
aspx?o=245908), published 1 March 
2005, concluded that there was not 
enough evidence to support the use of 
these drugs for all patients. However, 
responses received from stakeholders 
during consultation on this ﬁ  rst draft 
suggested that the drugs may be more 
effective for certain groups of people. 
NICE, therefore, asked the pharmaceutical 
companies involved in the appraisal to 
look for evidence to support this, from 
the data in their clinical trials. 
    In conclusion, “the Committee 
considered not just the initial evidence 
and submissions, but also the comments 
raised in consultation on the ﬁ  rst 
Appraisal Consultation Document 
(notably the improved infrastructure 
around dementia care) and the evidence 
that was submitted during consultation 
and the additional analyses undertaken. 
The Committee concluded that taking all 
these factors into account, the resulting 
estimates of cost effectiveness could 
be considered sufﬁ  ciently acceptable 
to allow the prescribing of AChE 
inhibitors,” donepezil, galantamine, and 
rivastigmine, for people with Alzheimer’s 
disease of moderate severity only (that is, 
those with an MMSE score between ten 
and 20). 
    As in the earlier draft, the committee 
“noted, however, that the evidence 
available on the long-term effectiveness 
of the AChE inhibitors on outcomes of 
importance to people with Alzheimer’s 
disease and their carers, such as quality 
of life and delayed time to nursing home 
placement, was limited and largely 
inconclusive.”
    As for memantine, it continued to be 
“not recommended as a treatment option 
for people with Alzheimer’s disease 
except as part of properly constructed 
clinical studies.” 
  NICE Recommendations on Cholinesterase Inhibitors
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the trial reports as a safe and effective 
means of treating vascular dementia. 
After a pooled analysis of the two trials, 
the authors wrote that “the results 
... are somewhat confusing,” and 
“further data on donepezil’s impact on 
executive functioning would be certainly 
desirable” [18,19].
    At the time of writing this article, the 
data from these vascular dementia trials 
have not been considered sufﬁ  cient 
evidence to license donepezil for 
treating vascular dementia. However, 
the positive messages contained in the 
published RCTs may promote the off-
label use of the drug.
  Dementia  Associated  with 
Parkinson Disease and Dementia 
with Lewy Bodies
    A Cochrane systematic review identiﬁ  ed 
only one RCT (involving 120 patients) 
of the efﬁ  cacy of rivastigmine in 
patients with probable dementia with 
Lewy bodies [20,21]. The Cochrane 
reviewers concluded that the trial 
“showed no statistically signiﬁ  cant 
difference between the two groups at 
20 weeks. A possible beneﬁ  cial effect 
on neuropsychiatric features was found 
only in analysis of observed cases, and 
may therefore be due to bias.” Hence 
the evidence of any beneﬁ  t is currently 
weak [21]. 
    Two clinical trials have investigated 
the effect of cholinesterase inhibitors in 
patients with dementia associated with 
Parkinson disease. The ﬁ  rst one [22], 
which found a trend (not statistically 
signiﬁ  cant) toward better scores on 
the ADAS-cog is not further discussed 
here because of its small size (only 22 
patients were randomized to receive 
donepezil or placebo). 
    The second trial, by Emre et al., 
investigated the effect of rivastigmine 
in 541 highly selected patients 
recruited from an unspeciﬁ  ed number 
of centers from 12 countries [23]. 
Patients included in the trial had 
received a diagnosis of dementia 6.6 ± 
5.2 years (treated arm) and 7.3 ± 5.2 
years (placebo arm) after the diagnosis 
of Parkinson disease. It would be 
difﬁ  cult to ﬁ  nd such a population in a 
clinical setting for a number of reasons. 
Beyond the diagnostic challenge of 
differentiating dementia associated 
with Parkinson disease from dementia 
of the Lewy body type, there is also 
evidence that the risk of dementia in 
Parkinson disease is associated with 
age and severity of extrapyramidal 
signs, and the mean time from onset 
of Parkinson disease to dementia is 
estimated to be 10.5 years [24–26]. But 
the exact clinical implications of this 
RCT are still not clear.
    The outcome measures used in 
Emre and colleagues’ trial were the 
ADAS-cog and the Alzheimer Disease 
Cooperative Study–Clinician’s Global 
Impression of Change scale. 
    In their trial, the authors considered a 
mean improvement of 2.25 points in the 
ADAS-cog score as clinically meaningful, 
even though this scale has never been 
used to monitor the progression rate of 
dementia in Parkinson disease. Among 
adverse events, Parkinsonian symptoms 
were reported more frequently in 
the rivastigmine group than in the 
placebo group. The authors concluded 
that rivastigmine was associated with 
moderate but signiﬁ  cant improvements 
in all symptoms of dementia associated 
with Parkinson disease, but also with 
high rates of adverse events, and that 
the ﬁ  ndings may have implications for 
clinical practice. But the exact clinical 
implications of this RCT are still not 
clear.
  Mild  Cognitive  Impairment: 
A New Clinical Entity or a New 
Market Frontier?
    Whether MCI can be considered 
a clinical entity is still a matter of 
debate (for example, Gauthier and 
Touchon have argued that “there is 
epidemiological evidence that many 
subjects labeled as having MCI do 
not worsen over time and may revert 
to normal cognitive abilities” [27]). 
Nevertheless, speciﬁ  c drug treatment 
for MCI has been proposed.
    Two RCTs have been conducted 
to investigate whether donepezil 
delays the onset of dementia in 
people with MCI. These studies 
failed to demonstrate any efﬁ  cacy, 
while showing a worse safety proﬁ  le 
among patients receiving active drug 
compared with the placebo group. In 
the ﬁ  rst published trial [28], signiﬁ  cant 
treatment effects were not seen in 
the primary efﬁ  cacy measures, while 
more patients treated with donepezil 
experienced adverse events compared 
with patients treated with placebo (88% 
versus 73%). Despite this negative 
result, a new trial was conducted by 
Petersen et al., comparing donepezil, 
vitamin E, and placebo [29]. This study 
did not show a signiﬁ  cant difference 
among the three groups in the rate of 
progression from MCI to Alzheimer 
disease over a three-year period. 
Nevertheless, the authors stress some 
limited effects on secondary measures: 
a reduced likelihood of progression 
to Alzheimer disease only during the 
ﬁ  rst 12 months of treatment, and a 
beneﬁ  t of donepezil among carriers 
of one or more apolipoprotein E ε4 
throughout the three-year follow-up. 
This latter claim, in particular, was not 
supported by the data as the study was 
not statistically powered to evaluate 
the effect of the treatment in separate 
groups of apolipoprotein E ε4 carriers.
    Harms-related data were inadequate: 
the ﬂ  ow of participants through the 
study phases was not described; the 
reasons and timing for discontinuation 
per treatment arm were not reported; 
only adverse events observed in at least 
5% of patients were reported; and 
the causes of the 23 deaths observed 
(17 in the double-blind phase and six 
in the subsequent open-label phase) 
were not speciﬁ  ed. In the double-blind 
phase, a higher number of deaths 
was observed in the donepezil arm 
(  n   = 7) compared with the vitamin E 
arm (  n   = 5) and the placebo arm (  n   
= 5). For the six deaths that occurred 
during the open-label phase, the 
original arm (active drug or placebo 
in the previous double-blind phase) 
was not reported. (The distribution 
of these six deaths across the three 
arms of the trial in the open phase was 
subsequently reported by Jelic et al. 
[30]—there were three deaths in the 
donepezil group, one in the vitamin 
E group, and two in the placebo arm; 
thus, the total number of deaths per 
arm in the whole trial was ten in the 
donepezil group [three from cardiac 
arrest], six in the vitamin E group, 
and seven in the placebo group.) 
Although Petersen et al. conceded that 
the results “do not provide support 
for a clear recommendation for the 
use of donepezil in persons with mild 
cognitive impairment,” they did suggest 
that their ﬁ  ndings “could prompt a 
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discussion between the clinician and 
the patient about this possibility” [29].
    Two trials, each lasting two years 
and not yet published, evaluated the 
effect of galantamine on a total of 
2,048 patients with MCI randomized to 
receive galantamine or placebo [31,32]. 
Overall, the studies did not show that 
the drug could improve cognition 
or delay the conversion to dementia. 
Increased mortality (mostly due to 
myocardial infarction and stroke) 
was observed among patients treated 
with galantamine compared with 
patients given placebo. On the basis of 
these results, the US Food and Drug 
Administration issued a safety warning 
concerning galantamine [33].
    In these trials, the treatment 
duration (two years) was longer 
than that of most previous RCTs on 
Alzheimer disease (typically only six 
months). The short trials on Alzheimer 
disease had shown no increased 
mortality associated with cholinesterase 
inhibitors compared with placebo. 
In clinical practice, though, these 
drugs would likely be prescribed for 
several years, and the galantamine 
trials [31,32] have shown that such 
prolonged use may be associated with 
increased mortality. A recent review on 
clinical trials in MCI concluded that 
none of the reviewed studies met their 
primary objectives; that is, none of the 
trials showed a beneﬁ  t of cholinesterase 
inhibitors in delaying the conversion 
to dementia or in slowing symptom 
progression [30].
  Conclusion
    At present, donepezil, galantamine, 
and rivastigmine are licensed only for 
the treatment of mild to moderate 
Alzheimer disease. The treatment effect 
is modest, and there is evidence of wide 
variability in the outcomes reported: 
“some patients will have improved, 
others stayed the same, while others will 
have deteriorated. This variance should 
be comparative in both the treatment 
and the placebo groups but care should 
be taken over the interpretation of the 
mean scores” [34]. 
    However, a minority of people 
with Alzheimer disease may beneﬁ  t 
from the cholinesterase inhibitors, 
and further research is needed to 
identify these subgroups of people, 
considering, in particular, long-term 
and worthwhile improvements such 
as delay in institutionalization. A 
cohort study of the effectiveness of 
cholinesterase inhibitors in Alzheimer 
disease has been conducted in Italy 
on 5,462 patients [35]. This study 
showed that the patients most likely 
to respond to treatment are those 
without concomitant diseases and 
those who had demonstrated an 
early response at three months. 
Response to treatment did not vary 
among groups with different Mini 
Mental State Examination (MMSE) 
scores at baseline. Based on these 
results, we suggest that physicians 
should accurately reevaluate their 
patients after three months of therapy, 
and should communicate realistic 
information to patients and their 
families about the very modest beneﬁ  ts 
of these drugs.
    Since 1996, when the ﬁ  rst 
cholinesterase inhibitor was licensed 
in the US for the symptomatic 
treatment of Alzheimer disease, each 
new published trial on the effect of 
cholinesterase inhibitors on the various 
different forms of dementia has raised 
new questions about the beneﬁ  t–risk 
proﬁ  le of these drugs. Reduced 
cholinergic neurotransmission was the 
rationale for the use of cholinesterase 
inhibitors in patients with dementia. 
Nevertheless, what seemed a 
biologically plausible intervention has 
not led to a proven, real improvement 
in patients’ well-being.   
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